Welcome to our dedicated page for Barrick Mining Corporation news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining Corporation stock.
Barnes Group Inc. (NYSE: B) maintains its position as a global leader in precision industrial technologies and aerospace solutions. This news hub provides investors and industry professionals with essential updates on corporate developments, financial performance, and strategic initiatives.
Access timely updates spanning earnings announcements, product innovations, and operational milestones. Our curated collection features official press releases alongside market analysis relevant to Barnes Grp's industrial and aerospace segments.
Key coverage areas include manufacturing advancements in transportation systems, aerospace component developments, and strategic partnerships across global markets. The repository serves as a reliable resource for understanding the company's impact on sectors ranging from healthcare infrastructure to defense technologies.
Bookmark this page for streamlined access to Barnes Grp's latest financial disclosures and operational updates. Regularly refreshed content ensures stakeholders maintain current awareness of this engineering leader's market position and technological contributions.
Fortunafi has announced the tokenization of Hilbert Capital's V1 Fund on Coinbase's Base, an Ethereum Layer-2 blockchain. Hilbert Capital, the asset management division of Nasdaq-listed Hilbert Group AB (NASDAQ: HILB B), joins Fortunafi's Tokenized Asset Protocol (TAP) app. The Hilbert V1 Fund aims to deliver absolute returns through an algorithmic market-neutral strategy, leveraging cryptoasset market properties for superior risk-adjusted returns.
Hilbert Capital, established in 2017, has a 7-year strategy performance track record and a team of 16 investment professionals, including 4 quantitative PhDs. This partnership is expected to expand Reservoir's reach and provide a new way of sourcing assets for Hilbert, while generating yield for Fortunafi's protocol users. The collaboration is seen as mutually beneficial, combining Fortunafi's crypto expertise with Hilbert's trading operation.
Barnes Group Inc. (NYSE: B) has announced its third quarter 2024 earnings conference call and webcast, scheduled for Friday, October 25, 2024. The company will release its financial results before the market opens and host a conference call at 8:30 a.m. (ET) to discuss the results and outlook. Investors can access the call through a live audio webcast on Barnes' website or via direct dial. The call will be recorded and available for playback until November 1, 2024. Supplemental materials will be posted on the company's Investor Relations section prior to the conference call.
BioArctic AB (Nasdaq Stockholm: BIOA B) has announced the publication of results from two phase 1 studies of exidavnemab in The Journal of Clinical Pharmacology. Exidavnemab is a monoclonal antibody targeting aggregated forms of α-synuclein, aimed at treating diseases like Parkinson's disease. The studies, conducted with AbbVie, involved 98 healthy volunteers, with 85 receiving exidavnemab. Results showed that exidavnemab was generally well-tolerated with an excellent half-life of approximately 30 days. The drug's high affinity and selectivity toward pathological α-synuclein aggregates are key for maintaining high target binding in the brain. CEO Gunilla Osswald expressed anticipation for starting the phase 2a study later this year.
Guidehouse, a global consultancy, has partnered with Hexagon, a digital reality solutions leader, to drive innovation in the public sector. This collaboration aims to enhance operational efficiency, transparency, and performance of government agencies throughout their assets' lifecycle. Key benefits include:
- Enhanced operational efficiency and data-driven decision-making
- Improved transparency and accountability in asset management
- Modernized solutions for mission-critical needs and lifecycle cost management
- Optimized lifecycle asset performance
The partnership combines Hexagon's cutting-edge technology with Guidehouse's public-sector expertise to deliver comprehensive solutions for complex government challenges, from asset acquisition and deployment to maintenance and decommissioning.
BioArctic AB announced that its partner Eisai received Marketing Authorization from the MHRA in Great Britain for Leqembi (lecanemab) to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in specific adult patients. This marks the first authorization in Europe for a medicine targeting an underlying cause of Alzheimer's disease.
Lecanemab selectively binds to and clears toxic Aβ protofibrils from the brain. The approval was based on the Phase 3 Clarity AD clinical trial, which met its primary and key secondary endpoints. Common adverse reactions include infusion-related reactions and amyloid-related imaging abnormalities.
Eisai is working with health authorities to make Leqembi available to eligible patients. The antibody was originally developed by BioArctic, resulting from a collaboration with Eisai.
BioArctic AB (NASDAQ Stockholm: BIOA B) has addressed recent rumors circulating in British media regarding the imminent approval of lecanemab in Great Britain. The company stated that it has not been informed of any decision made by the relevant authorities and is therefore unable to comment on these speculations. BioArctic has committed to updating the market if new information becomes available. This statement was released for public disclosure on August 22, 2024, at 08:34 a.m. CET. The company has provided contact information for its VP of Communications and IR, Oskar Bosson, for further inquiries.
Barnes Group Inc. (NYSE: B), a global provider of engineered products and industrial technologies, has announced its participation in the 2024 Jefferies Industrials Conference. Thomas J. Hook, President and CEO, will present to investors on September 5, 2024, at 11:35 a.m. ET.
A live webcast of the presentation will be available on the company's website at www.onebarnes.com in the Investor Relations section. Investors can also access a replay for 90 days following the presentation. Barnes has noted that the conference date and time may be subject to change, with any updates to be posted on their website.
BioArctic AB (NASDAQ Stockholm: BIOA B) has announced the upcoming release of its second quarter report for April - June 2024 on August 29, 2024, at 08:00 a.m. CET. Following the report's publication, the company will host an audiocast with teleconference at 09:30 CET on the same day. CEO Gunilla Osswald and CFO Anders Martin-Löf will present and discuss the quarterly results, followed by a Q&A session. Investors, analysts, and media are invited to participate via webcast or teleconference. The webcast will be available on-demand on BioArctic's corporate website after the presentation.
ETQ, a Hexagon company, has appointed Prashant Darisi as Chief Product Officer. Darisi will manage the product roadmap for ETQ's quality management system (QMS) software platform, ETQ Reliance®. His responsibilities include expanding the software into new areas leveraging AI and predictive quality analytics, as well as integrating QMS with connected worker capabilities.
Darisi brings over 20 years of experience in executive positions, having previously served as Vice President and General Manager at Everbridge. He has expertise in enterprise SaaS products, AI/ML strategy, and product management. ETQ CEO Vick Vaishnavi expressed confidence in Darisi's ability to drive product strategy that will benefit customers globally, especially as ETQ explores integration opportunities within the Hexagon environment.
BioArctic AB's partner Eisai announced the approval of Leqembi (lecanemab) for the treatment of Alzheimer's disease in the United Arab Emirates (UAE). The approval is based on the successful Phase 3 Clarity AD study, where Leqembi met its primary and key secondary endpoints. Leqembi is the first approved treatment shown to reduce disease progression and slow cognitive decline by targeting amyloid-beta aggregates in the brain.
In the UAE, 4.09% of those over 60 have dementia, with Alzheimer's being the most common cause. Leqembi is already approved in several countries, including the U.S., Japan, and China. The antibody was originally developed by BioArctic, based on research by Professor Lars Lannfelt. Eisai is responsible for clinical development and commercialization, with Biogen commercializing in the UAE.
FAQ
What is the current stock price of Barrick Mining Corporation (B)?
What is the market cap of Barrick Mining Corporation (B)?
